← All trials
NCT04649723
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2020
- Primary completion
- Dec 14, 2020
- Completion date
- Mar 26, 2021
- First posted
- Dec 2, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.